D
Debbie Frye
Researcher at University of Texas MD Anderson Cancer Center
Publications - 12
Citations - 658
Debbie Frye is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Chemotherapy. The author has an hindex of 8, co-authored 12 publications receiving 635 citations. Previous affiliations of Debbie Frye include University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center
Naoto T. Ueno,Aman U. Buzdar,Sonja E. Singletary,Fred C. Ames,Marsha D. McNeese,Frankie A. Holmes,Richard L. Theriault,Eric A. Strom,Barbara J. Wasaff,Lina Asmar,Debbie Frye,Gabriel N. Hortobagyi +11 more
TL;DR: In this paper, the authors reviewed the 20 years of experience at M. D. Anderson Cancer Center with a combined-modality approach against inflammatory breast carcinoma and found that a significant fraction of patients (28%) remained free of disease beyond 15 years.
Journal ArticleDOI
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation.
Thomas A. Buchholz,Susan L. Tucker,Lawrence Masullo,Henry Mark Kuerer,Jessica Erwin,Jessica Salas,Debbie Frye,Eric A. Strom,Marsha D. McNeese,George H. Perkins,Angela Katz,S. Eva Singletary,Kelly K. Hunt,Aman U. Buzdar,Gabriel N. Hortobagyi +14 more
TL;DR: Advanced disease at presentation and positive lymph nodes after chemotherapy predict for clinically significant rates of LRR, and achievement of pCR does not preclude the need for postmastectomy radiation if warranted by the pretreatment stage of the disease.
Journal ArticleDOI
Paclitaxel Improves the Prognosis in Estrogen Receptor—Negative Inflammatory Breast Cancer: The M. D. Anderson Cancer Center Experience
Massimo Cristofanilli,Ana M. Gonzalez-Angulo,Aman U. Buzdar,Shu Wan Kau,Debbie Frye,Gabriel N. Hortobagyi +5 more
TL;DR: It may be concluded that the addition of paclitaxel to anthracycline-based therapy resulted in a statistically significant improvement in outcome in patients with ER-negative inflammatory breast cancer.
Journal Article
A Detailed Evaluation of Cardiac Toxicity: A Phase II Study of Doxorubicin and One- or Three-Hour-Infusion Paclitaxel in Patients with Metastatic Breast Cancer
Sharon H. Giordano,Daniel J. Booser,James L. Murray,Nuhad K. Ibrahim,Z. Rahman,Vicente Valero,Richard L. Theriault,Marguerite F. Rosales,Edgardo Rivera,Debbie Frye,Michael S. Ewer,Nelson G. Ordóñez,Aman U. Buzdar,Gabriel N. Hortobagyi +13 more
TL;DR: When the doxorubicin dose exceeds 360 mg/m2, the combination of bolus doxorbicin and paclitaxel presents unacceptable cardiac risk.
Journal ArticleDOI
Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results
Banu Arun,Kapil Dhinghra,Vicente Valero,Shu Wan Kau,Kristine Broglio,Daniel J. Booser,Laura Guerra,Guosheng Yin,Ronald S. Walters,Aysegul Sahin,Nuhad K. Ibrahim,Aman U. Buzdar,Debbie Frye,Nour Sneige,Eric A. Strom,Merrick I. Ross,Richard L. Theriault,Saroj Vadhan-Raj,Gabriel N. Hortobagyi +18 more
TL;DR: A higher delivered dose intensity of doxorubicin with the FAC + G-CSF regimen did not result in a statistically significant higher pCR rate, however, patients who achieved a pCR experienced longer DFS and OS times.